ArticleHealth science reports2026
The Global Burden of Aortic Aneurysm and Its Attributable Risk Factors, 1990-2021: Results from the Global Burden of Disease Study 2021.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Aorta Is One Organ; Our Response Is Not: A Global Case for Systems Redesign in Acute Aortic Syndromes.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Aortic aneurysm (AA) is a potentially fatal aortic disorder, particularly when complicated by rupture. Using Global Burden of Disease 2021 estimates, this study reported worldwide changes in AA mortality, disability-adjusted life years (DALYs), and modeled risk-attributable burden from 1990 to 2021. Methods: We reported Global Burden of Disease 2021 estimates and summarized findings using counts, percentages, and age-standardized rates. Results: In 2021, the global age-standardized death rate for AA was 1.9 per 100,000, representing a 26.7% decrease since 1990. The global age-standardized DALY rate was 36.5 per 100,000, reflecting a 25.1% reduction. The highest national DALY rates per 100,000 were estimated in Armenia (192.8), Montenegro (178.9), and Nauru (114.5), while the lowest were in Saudi Arabia (5.1), Tajikistan (5.7), and Sri Lanka (6.7). The largest increases in age-standardized DALY rates occurred in Georgia (357.4%), Uzbekistan (320.6%), and Sudan (209.4%), whereas the greatest decreases occurred in Australia (-70.6%), Bermuda (-66.6%), and Canada (-65.9%). For both sexes, DALY rates were highest in the 95+ years group, indicating concentration of fatal burden at advanced age. Smoking, high systolic blood pressure, and high body mass index were the leading modeled contributors to global AA DALYs, accounting for 37.3%, 17.1%, and 8.0%, respectively. Conclusion: This report identified marked variation in AA burden, potentially related to differences in screening, diagnosis, treatment access, and broader health-system capacity. The results support targeted prevention, risk-factor control, and improved vascular care, especially in resource-limited settings. Reducing smoking and high systolic blood pressure may help lessen the future AA burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.